Abbott (ABT) and Reckitt Benckiser’s (RBGLY) unit Mead Johnson are not responsible for a young boy’s debilitating intestinal disease, a jury found on Thursday, reported Reuters. The ruling in the lawsuit that accused the companies of failing to warn of the risks of premature baby formulas is a victory for the companies following large losses in similar trials, notes the report. Shares of both parent companies’ stocks are trading higher on Friday following the ruling.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Raymond James says Edwards’ EARLY TAVR data also positive for Medtronic, Abbott
- Abbott initiates clinical trial of its CardioMems in advanced heart failure
- Abbott price target raised to $130 from $115 at Mizuho
- Abbott price target raised to $146 from $143 at UBS
- Abbott price target raised to $133 from $131 at Piper Sandler
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue